Inari Medical, Inc. Stock Price, News & Analysis

Inari Medical, Inc. (NASDAQ: NARI), a company dedicated to developing medical devices for venous diseases, announced its participation in the Canaccord Genuity MedTech Forum on November 17, 2022, at the Westin NY Grand Central Hotel. The company specializes in catheter-based mechanical thrombectomy devices, including the ClotTriever and FlowTriever systems, designed for non-surgical removal of clots from blood vessels. Both products are FDA 510(k)-cleared and CE marked, targeting deep vein thrombosis and pulmonary embolism.

Inari Medical, Inc. (NASDAQ: NARI) reported third-quarter 2022 revenue of $96.2 million, a 32% increase from the same quarter in 2021. The growth is attributed to U.S. commercial expansion, increased procedure adoption, and the launch of two new products, Protrieve and InThrill. Despite a net loss of $10.2 million for the quarter, the company ended with $319.2 million in cash and investments. Inari has raised its full-year revenue guidance to a range of $373 million to $375 million.

Inari Medical, Inc. (NASDAQ: NARI) announced positive results from the 500-patient CLOUT registry, confirming the ClotTriever system's effectiveness for treating deep vein thrombosis (DVT). Over 90% of patients achieved complete thrombus extraction with only one serious device-related adverse event. The analysis also revealed that ClotTriever had nearly double the thrombus clearance compared to standard treatment methods, along with a 13% reduction in post-thrombotic syndrome. Inari aims to establish ClotTriever as a standard of care for DVT and pulmonary embolism (PE) patients.

Inari Medical, Inc. (NASDAQ: NARI) plans to release its third quarter 2022 financial results on November 2, 2022. The medical device company, focused on treating venous diseases, will host a conference call at 1:30 p.m. PT to discuss its results and recent highlights. Inari's product line includes the ClotTriever and FlowTriever systems, designed for the non-surgical removal of clots from large vessels, addressing conditions like deep vein thrombosis and pulmonary embolism. Interested parties can access the call via telephone or through their investor relations website.

Inari Medical (NASDAQ: NARI) announced positive results from the 800-patient FLASH registry, presented at the 2022 TCT conference. The study, evaluating the FlowTriever system in treating pulmonary embolism (PE), reported a low major adverse event rate of 1.8% and 30-day all-cause mortality of just 0.8%. The findings underscore FlowTriever's strong safety profile and clinical effectiveness, suggesting it may enhance PE treatment outcomes. Inari aims to continue developing high-quality evidence through ongoing studies like the FLAME registry and PEERLESS trial.

Inari Medical, Inc. (NASDAQ: NARI) announced its first Analyst and Investor Day scheduled for September 15, 2022, at its headquarters in Irvine, California. The event will involve a comprehensive update on the company’s business progress and future plans via a webcast set to begin at 9 a.m. Pacific Time. Participation is open to interested stakeholders, who can pre-register through a provided link. Additionally, a replay of the presentation will be available for 90 days on the company's Investor Relations website.

Inari Medical, Inc. (NASDAQ: NARI) announced the presentation of three new data sets from pivotal clinical studies at the 2022 TCT and VEINS conferences. The FLASH registry will showcase results from 800 patients treated with the FlowTriever system, focusing on safety and clinical outcomes, presented on September 18. The CLOUT registry results involving 500 patients will be shared on October 30-31, evaluating the ClotTriever system's effectiveness. A comparison of CLOUT data with ATTRACT outcomes will also be highlighted. These studies aim to refine the treatment standards for venous thromboembolism (VTE).

Inari Medical (NASDAQ: NARI) announced the upcoming enrollment of the DEFIANCE trial, a randomized controlled study aimed at assessing the effectiveness of the ClotTriever System for treating iliofemoral deep vein thrombosis (DVT) compared to traditional anticoagulation therapy. This trial will involve 300 patients across 60 centers globally. DEFIANCE is expected to set new treatment standards and reduce post-thrombotic syndrome risks. It follows the PEERLESS trial, further bolstering Inari's commitment to pioneering clinical research in vascular treatments.

Inari Medical, Inc. (NASDAQ: NARI) announced its participation in two upcoming investor conferences. The first is the Wells Fargo Healthcare Conference on September 9, 2022, at 8:35 a.m. Eastern Time in Boston, MA, featuring a fireside chat. The second is the Morgan Stanley 20th Annual Global Healthcare Conference on September 12, 2022, at 8:10 a.m. Eastern Time in New York, NY, also a fireside chat. Interested parties can access live audio webcasts through the company’s website.